Elekta AB Unsponsored ADR Class B ( (EKTAY) ) has released its Q4 earnings. Here is a breakdown of the information Elekta AB Unsponsored ADR Class B presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Elekta AB Unsponsored ADR Class B is a prominent player in the healthcare sector, specializing in advanced medical devices and software solutions for cancer treatment and brain disorders. The company is known for its innovative approach in radiotherapy and radiosurgery, providing cutting-edge technology to healthcare providers worldwide.
In its latest earnings report for the fiscal year ending April 2025, Elekta reported a mixed financial performance. The company saw a 6% increase in net sales for the fourth quarter at constant exchange rates, primarily driven by strong performances in Europe and the Asia-Pacific regions. However, the full-year reported sales saw a slight decline of 1% due to currency fluctuations.
Key financial metrics highlighted in the report include an improved adjusted gross margin of 40.3% in the fourth quarter, the highest in five years, supported by increased volumes and favorable product mix. Despite a strong cash flow of SEK 1,248 million after continuous investments, the company faced a net income loss of SEK 381 million in the fourth quarter, impacted by a significant non-cash impairment of SEK 1,064 million due to discontinued R&D projects.
Looking ahead, Elekta’s management remains optimistic about future growth, expecting year-over-year sales increases despite current market conditions. The company anticipates further expansion in gross and EBIT margins, driven by new product launches and price adjustments, aiming to return to pre-pandemic levels of profitability.